Yuhong Fang

TL;DR: This work deployed innovative high-throughput screening strategies to identify a small molecule cocktail that dramatically improves viability of hPSCs and their differentiated progeny and discovered that the combination of Chroman 1, Emricasan, Polyamines, and Trans-ISRIB enhanced cell survival of genetically stable hPSC by simultaneously blocking several stress mechanisms that otherwise compromise cell structure and function.

TL;DR: A comprehensive suite of in vitro preclinical drug development assays that can be used as a tool-box to identify lead compounds for mIDH drug discovery programs, as well as what is believed to be the most comprehensive publically available dataset on the top m IDH inhibitors.

TL;DR: A lead optimization campaign is focused on a pyrazole-based series of compounds, using structure-based design concepts, coupled with optimization of cellular potency, in vitro drug-target residence times, and in vivo PK properties, to identify first-in-class inhibitors that demonstrate LDH inhibition in vivo.

TL;DR: A medicinal chemistry campaign around a 7,7-dimethyl-7,8-dihydro-2H-1λ2-quinoline-2,5(6H)-dione screening hit against the R132H and R132C mutant forms of isocitrate dehydrogenase (IDH1) was reported in this article.